Clinical Trials · global
Telomere Therapy Takes on Advanced Lung Cancer: MAIA Phase 3 Trial Completes Randomization of 65 Patients
A strategy that uses ateganosine to attack cancer cell telomeres before proceeding to immunotherapy is being tested in a Phase 3 trial. Taiwan is among the trial locations, but beyond enrollment progress, the key question is whether the approach can extend patients’ survival.
When advanced non-small cell lung cancer continues to progress after immunotherapy or chemotherapy, patients and physicians face the difficult question of whether the next treatment can extend life. MAIA Biotechnology is seeking an answer with a drug candidate that targets cancer cell telomeres. On September 22, 2026, the company announced that 65 patients had been randomized in the Phase 3 THIO-104 trial, advancing the clinical evaluation of this third-line treatment strategy.
According to the company’s announcement, the trial has activated 38 sites across Taiwan, Romania, Turkey, Georgia, Poland, and Hungary. A same-day report by S&P Capital IQ published on MarketScreener also recorded the same enrollment and site figures. MAIA has set a target of randomizing more than 100 patients by the end of the year, but this remains the company’s expectation, rather than a milestone already achieved.
THIO-104 is a multicenter, randomized, open-label trial enrolling patients with advanced disease whose prior regimens containing immune checkpoint inhibitors and/or chemotherapy were ineffective or led to resistance, with continued disease progression. The study compares ateganosine followed by a PD-(L)1 immune checkpoint inhibitor with chemotherapy selected by the study physician. The primary efficacy endpoint is overall survival, and safety and tolerability will also be assessed.
The concept behind this treatment is to first disrupt the mechanism cancer cells use to maintain the ends of their chromosomes, then proceed to immunotherapy. According to the company, ateganosine, also known as THIO, is a modified nucleoside that can interfere with telomeric DNA through the action of telomerase, triggering a damage response. This provides a biological rationale for sequential treatment, but whether the mechanism can translate into a survival benefit for patients remains a question for human trials.
The announcement also cited an interim disease control rate of 90.5%. That figure comes from a separate Phase 2 trial, THIO-101, and is not a Phase 3 result from this update. Disease control rate generally encompasses tumor shrinkage and stable disease and cannot be directly equated with longer survival. Comparisons with chemotherapy figures from other studies would also be affected by differences in patient characteristics and assessment methods and cannot replace a randomized controlled trial.
This news therefore reflects progress in trial execution; it does not yet disclose an efficacy comparison between the two THIO-104 groups or complete safety data. The next evidence with real clinical significance will come from survival follow-up and adverse event results. These will determine whether targeting telomeres first, followed by immunotherapy, can deliver measurable benefits for patients who have already undergone multiple treatments.